Courtesy of Kenneth Taubenslag, MD, Edward Cherney, MD, and Anita Agarwal, MD.
Deferoxamine (also called desferrioxamine) toxicity. A, Fundus photographs show pigmentary macular changes in a patient with sickle cell disease who was receiving deferoxamine for transfusional hemosiderosis. B, Corresponding FAF images highlight the classic reticular pigment epithelial changes. C, SD-OCT demonstrates ellipsoid loss and hyperreflective deposits at the level of the RPE.